(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 April 2011 (28.04.2011)

PCT

(10) International Publication Number
WO 2011/049946 A1

(51) International Patent Classification:
A61K 31/4196 (2006.01) *A61K 45/06* (2006.01)
A61K 31/337 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2010/053199

(22) International Filing Date:
19 October 2010 (19.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/279,330 19 October 2009 (19.10.2009) US
61/335,778 11 January 2010 (11.01.2010) US

(71) Applicant *(for all designated States except US)*: **SYNTA PHARMACEUTICALS CORP.** [US/US]; 45 Hartwell Avenue, Lexington, Massachusetts 02421 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BLACKMAN, Ronald, K.** [US/US]; 140 Sewall Avenue #2, Brookline, Massachusetts 02446 (US). **FOLEY, Kevin, Paul** [US/US]; 4402 Merchant Square Place, Landsdale, Pennsylvania 19446 (US). **PROIA, David** [US/US]; 30 Silver Lake Avenue, Newton, Massachusetts 02458 (US).

(74) Agents: **DAVIS, Steven, G.** et al.; FOLEY & LARDNER LLP, 111 Huntington Avenue, Boston, Massachusetts 02199 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

WO 2011/049946 A1

(54) **Title**: COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS



(I)

(57) **Abstract**: Disclosed is a method for treating a subject with cancer, comprising administering to the subject an effective amount of paclitaxel or a paclitaxel analogue and an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.